The synthetic drug fenoldopam mesylate (FM) may have a renoprotective role, and a "renal dose" of 0.1 µg/kg/min intravenous (IV) infusion of FM has been reported as able to increase renal blood flow without affecting systemic blood pressure. But conclusive data are still lacking. We aimed to investigate by color-Doppler ultrasonography the effects of IV administration of FM at this dosage in hypertensive chronic kidney disease (CKD) patients, and verify whether it may induce any systemic hemodynamic alteration.
Rovella, V., Ferrannini, M., Tesauro, M., Marrone, G., Busca, A., Sorge, R., et al. (2019). Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease. JN. JOURNAL OF NEPHROLOGY, 32(1), 75-81 [10.1007/s40620-018-0496-0].
Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease
Rovella V.;Tesauro M.;Sorge R.;Manca di Villahermosa S.;Di Daniele N.;Noce A.
2019-01-01
Abstract
The synthetic drug fenoldopam mesylate (FM) may have a renoprotective role, and a "renal dose" of 0.1 µg/kg/min intravenous (IV) infusion of FM has been reported as able to increase renal blood flow without affecting systemic blood pressure. But conclusive data are still lacking. We aimed to investigate by color-Doppler ultrasonography the effects of IV administration of FM at this dosage in hypertensive chronic kidney disease (CKD) patients, and verify whether it may induce any systemic hemodynamic alteration.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.